The immune phenotype may relate to cancer development in kidney transplant recipients

Kidney International

Volumn 86, Issue 1, 2014, Pages 175-183

  Hope, Christopher M ^a,b   Grace, Blair S ^b,c   Pilkington, Katherine R ^d,e   Coates, Patrick T ^a,b   Bergmann, Ivo P ^f   Carroll, Robert P ^a,b  

^a Central and Northern Adelaide Renal and Transplantation Service   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry   (Australia)

^d HANSON INSTITUTE   (Australia)

^e South Australia Pathology ^*  (Australia)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

cancer; immune; phenotype; T cells; transplantation; Tregs

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CD19 ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CYCLOSPORIN A; EVEROLIMUS; IMMUNOGLOBULIN D; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; IMMUNOSUPPRESSIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CELL COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNE RESPONSE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; NEOPLASM; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REGULATORY T LYMPHOCYTE; SENSITIVITY AND SPECIFICITY; SKIN CARCINOGENESIS; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; ADVERSE EFFECTS; B LYMPHOCYTE; CARCINOMA, SQUAMOUS CELL; COHORT ANALYSIS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; NATURAL KILLER CELL; NEOPLASMS; ODDS RATIO; RISK FACTOR; SINGLE BLIND PROCEDURE; SKIN NEOPLASMS; TUMOR RECURRENCE;

ADULT; B-LYMPHOCYTES; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; ODDS RATIO; PROSPECTIVE STUDIES; RISK FACTORS; SINGLE-BLIND METHOD; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84903792374     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.538     Document Type: Article

References (45)

1. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-2831. (Pubitemid 44969182)
2. Wisgerhof HC, van der Geest LG, de Fijter JW et al. Incidence of cancer in kidney-Transplant recipients: A long-Term cohort study in a single center. Cancer Epidemiol 2011; 35: 105-111.
3. Moloney FJ, Kelly PO, Kay EW et al. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg 2004; 30: 674-678. (Pubitemid 38525900)
4. Ramsay HM, Fryer AA, Reece S et al. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000; 36: 167-176. (Pubitemid 30432579)
5. Carroll RP, Ramsay HM, Fryer AA et al. Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: A prospective study in Queensland, Australia. Am J Kidney Dis 2003; 41: 676-683. (Pubitemid 36278387)
6. Peat B, Insull P, Ayers R. Risk stratification for metastasis from cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg 2012; 82: 230-233.
7. Brantsch KD, Meisner C, Schonfisch B et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: A prospective study. Lancet Oncol 2008; 9: 713-720.
8. Tessari G, Naldi L, Boschiero L et al. Incidence of primary and second cancers in renal transplant recipients: A multicenter cohort study. Am J Transplant 2013; 13: 214-221.
9. Ducloux D, Carron PL, Motte G et al. Lymphocyte subsets and assessment of cancer risk in renal transplant recipients. Transpl Int 2002; 15: 393-396. (Pubitemid 36061753)
10. Carroll RP, Segundo DS, Hollowood K et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol 2010; 21: 713-722.
11. Baan CC, Velthuis JH, van Gurp EA et al. Functional CD25(bright+) alloresponsive T cells in fully immunosuppressed renal allograft recipients. Clin Transplant 2007; 21: 63-71. (Pubitemid 46189589)
12. Yoshizawa A, Ito A, Li Y et al. The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant Proc 2005; 37: 37-39. (Pubitemid 40459681)
13. Karagoz B, Bilgi O, Gumus M et al. CD8+CD28-cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol 2010; 27: 29-33.
14. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 2013; 31: 1317-1323.
15. Carroll RP, Hester J, Wood KJ et al. Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype. Nephrol Dial Transplant 2013; 28: 462-465.
16. Euvrard S, Morelon E, Rostaing L et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329-339.
17. Carroll RP, Chapman Jr. Can the risk of skin cancer after transplantation be reduced by mTOR Inhibitors? Am J Kidney Dis 2013; 61: 698-700.
18. Thornton AM, Korty PE, Tran DQ et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010; 184: 3433-3441.
19. Alamartine E, Sabido O, Berthoux F. In-vitro effects of cyclosporin A, FK506, 6-mercaptopurine, and prednisolone on lymphokine-Activated killer cells. Nephrol Dial Transplant 1994; 9: 1456-1461. (Pubitemid 24310291)
20. Vacher-Coponat H, Brunet C, Moal V et al. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine. Transplantation 2006; 82: 558-566. (Pubitemid 44290263)
21. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640. (Pubitemid 33043908)
22. Chidrawar SM, Khan N, Chan YL et al. Ageing is associated with a decline in peripheral blood CD56bright NK cells. Immun Ageing 2006; 3: 10.
23. Gurkan S, Luan Y, Dhillon N et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010; 10: 2132-2141.
24. Ducloux D, Bamoulid J, Courivaud C et al. Thymic function, antithymocytes globulins, and cancer after renal transplantation. Transpl Immunol 2011; 25: 56-60.
25. Colonna-Romano G, Aquino A, Bulati M et al. Memory B cell subpopulations in the aged. Rejuvenation Res 2006; 9: 149-152.
26. Newell KA, Asare A, Kirk AD et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836-1847.
27. Pallier A, Hillion S, Danger R et al. Patients with drug-free long-Term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78: 503-513.
28. Lim HW, Hillsamer P, Banham AH et al. Cutting edge: Direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol 2005; 175: 4180-4183. (Pubitemid 41361949)
29. Saze Z, Schuler PJ, Hong CS et al. Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood 2013; 122: 9-18.
30. Schena F, Volpi S, Faliti CE et al. Dependence of immunoglobulin class switch recombination in B cells on vesicular release of ATP and CD73 ectonucleotidase activity. Cell Rep 2013; 3: 1824-1831.
31. Rahimpour A, Mattarollo SR, Yong M et al. gammadelta T cells augment rejection of skin grafts by enhancing cross-priming of CD8 T cells to skinderived antigen. J Invest Dermatol 2012; 132: 1656-1664.
32. Braza MS, Klein B. Anti-Tumour immunotherapy with Vgamma9Vdelta2 T lymphocytes: From the bench to the bedside. Br J Haematol 2013; 160: 123-132.
33. Martinez-Llordella M, Puig-Pey I, Orlando G et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309-319. (Pubitemid 46096324)
34. Morita CT, Verma S, Aparicio P et al. Functionally distinct subsets of human gamma/delta T cells. Eur J Immunol 1991; 21: 2999-3007.
35. Yurchenko E, Levings MK, Piccirillo CA. CD4+ Foxp3+ regulatory T cells suppress gammadelta T-cell effector functions in a model of T-cell-induced mucosal inflammation. Eur J Immunol 2011; 41: 3455-3466.
36. Kobayashi H, Tanaka Y, Nakazawa H et al. A new indicator of favorable prognosis in locally advanced renal cell carcinomas: Gamma delta T-cells in peripheral blood. Anticancer Res 2011; 31: 1027-1031.
37. Couzi L, Levaillant Y, Jamai A et al. Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol 2010; 21: 181-188.
38. Ma C, Zhang Q, Ye J et al. Tumor-infiltrating gammadelta T lymphocytes predict clinical outcome in human breast cancer. J Immunol 2012; 189: 5029-5036.
39. Miller AM, Lundberg K, Ozenci V et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177: 7398-7405. (Pubitemid 44715110)
40. Himmel ME, MacDonald KG, Garcia RV et al. Helios+ and Helios-cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J Immunol 2013; 190: 2001-2008.
41. Zabransky DJ, Nirschl CJ, Durham NM et al. Phenotypic and functional properties of Helios+ regulatory T cells. PLoS One 2012; 7: E34547.
42. Harwood CA, Mesher D, McGregor JM et al. A surveillance model for skin cancer in organ transplant recipients: A 22-year prospective study in an ethnically diverse population. Am J Transplant 2013; 13: 119-129.
43. Vandenbroucke JP, von Elm E, Altman DG et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Ann Intern Med 2007; 147: W163-W194. (Pubitemid 351664503)
44. Nicholson JK, Hubbard M, Jones BM. Use of CD45 fluorescence and side-scatter characteristics for gating lymphocytes when using the whole blood lysis procedure and flow cytometry. Cytometry 1996; 26: 16-21. (Pubitemid 26110008)
45. Roederer M. Spectral compensation for flow cytometry: Visualization artifacts, limitations, and caveats. Cytometry 2001; 45: 194-205. (Pubitemid 33064141)